Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73611143" target="_blank" >RIV/61989592:15110/21:73611143 - isvavai.cz</a>

Výsledek na webu

<a href="https://com-mendeley-prod-publicsharing-pdfstore.s3.eu-west-1.amazonaws.com/" target="_blank" >https://com-mendeley-prod-publicsharing-pdfstore.s3.eu-west-1.amazonaws.com/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2020.029" target="_blank" >10.5507/bp.2020.029</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma

Popis výsledku v původním jazyce

Aims. Angiotensin converting enzyme inhibitors (ACEI) have been recently discussed in connection with the medical treatment of chronic subdural haematoma (CSDH). They may improve the treatment results. The objective of our study was to evaluate the impact of ACEI on the development of CSDH. The first question was to assess the impact of ACEI on postoperative CSDH healing. The second was to assess the impact of ACEI on the development of CSDH as such. Patients and Methods. The study recruited patients treated surgically for CSDH at our department in the 2013–2018 period. Based on medical records, we retrospectively evaluated the clinical condition of the patients, their history (mainly pharmacological – the use of ACEI) and the course of treatment focussing on the reoccurrence of disease ne-cessitating further therapeutic interventions. For the purpose of evaluating the impact of ACEI on postoperative CSDH healing, the patients were divided into two groups: those using ACEI and those without this medication. The results were compared. We also compared the prevalence of ACEI use in patients with CSDH with the prevalence of ACEI in the comparable population. The difference of the rates allowed us to evaluate the impact of ACEI on the development of CSDH itself. Results. Of the 217 patients after surgery for CSDH, 79 continued the use of ACEI; the remaining 138 patients did not use this medication. Patients using ACEI after the surgery experienced a recurrence in 24 (30.4%) cases; patients without ACEI in 37 (26.8%) cases. A negligibly higher number of recurrences was recorded in patients with postoperative use of ACEI, but this difference was not statistically significant (P=0.574). Of a total of 230 patients who underwent surgery for CSDH, 81 were using ACEI chronically (35.2%). In the control group of 100 patients, 38 (38.0%) patients used ACEI. The difference was not statistically significant (P=0.629), so it is not possible to assume that ACEIs influence the development of CSDH as such. Conclusion. The initial high hopes for a positive ACEI effect on the healing of CSDH are now waived after the publica-tion of several recent studies. According to our present knowledge, the development of CSDH does not appear to be influenced by ACEI use.

Název v anglickém jazyce

Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma

Popis výsledku anglicky

Aims. Angiotensin converting enzyme inhibitors (ACEI) have been recently discussed in connection with the medical treatment of chronic subdural haematoma (CSDH). They may improve the treatment results. The objective of our study was to evaluate the impact of ACEI on the development of CSDH. The first question was to assess the impact of ACEI on postoperative CSDH healing. The second was to assess the impact of ACEI on the development of CSDH as such. Patients and Methods. The study recruited patients treated surgically for CSDH at our department in the 2013–2018 period. Based on medical records, we retrospectively evaluated the clinical condition of the patients, their history (mainly pharmacological – the use of ACEI) and the course of treatment focussing on the reoccurrence of disease ne-cessitating further therapeutic interventions. For the purpose of evaluating the impact of ACEI on postoperative CSDH healing, the patients were divided into two groups: those using ACEI and those without this medication. The results were compared. We also compared the prevalence of ACEI use in patients with CSDH with the prevalence of ACEI in the comparable population. The difference of the rates allowed us to evaluate the impact of ACEI on the development of CSDH itself. Results. Of the 217 patients after surgery for CSDH, 79 continued the use of ACEI; the remaining 138 patients did not use this medication. Patients using ACEI after the surgery experienced a recurrence in 24 (30.4%) cases; patients without ACEI in 37 (26.8%) cases. A negligibly higher number of recurrences was recorded in patients with postoperative use of ACEI, but this difference was not statistically significant (P=0.574). Of a total of 230 patients who underwent surgery for CSDH, 81 were using ACEI chronically (35.2%). In the control group of 100 patients, 38 (38.0%) patients used ACEI. The difference was not statistically significant (P=0.629), so it is not possible to assume that ACEIs influence the development of CSDH as such. Conclusion. The initial high hopes for a positive ACEI effect on the healing of CSDH are now waived after the publica-tion of several recent studies. According to our present knowledge, the development of CSDH does not appear to be influenced by ACEI use.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BIOMEDICAL PAPERS-OLOMOUC

ISSN

1213-8118

e-ISSN

—

Svazek periodika

165

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

4

Strana od-do

175-178

Kód UT WoS článku

000660244900010

EID výsledku v databázi Scopus

2-s2.0-85108823131